EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533

David B Dix iD, Geetika Khanna, Lindsay A Renfro iD, Ian C Tfirn, Ethan A Smith, Maddy Artunduaga iD, Meryle J Eklund, Jesse K Sandberg iD, Lauren N Parsons, John A Kalapurakal, Peter F Ehrlich, Jennifer H Aldrink iD und 7 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-25-00532 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von David B Dix und 18 weiteren Autor:innen. Beteiligte Einrichtung: British Columbia Children's Hospital, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Wilms Tumor, Lung Neoplasms, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Children with favorable histology Wilms tumor (FHWT) with pulmonary metastases have inferior outcomes compared with those with localized disease. We evaluated the impact of pulmonary tumor burden within subgroups of similarly treated children with stage IV FHWT. METHODS Children with FHWT with pulmonary-only metastasis enrolled in AREN0533 were included. Lung nodule response assessment, by chest computed tomography after two cycles of vincristine/dactinomycin/doxorubicin (Regimen DD-4A) chemotherapy, identified rapid complete responses (RCRs) and slow incomplete pulmonary nodule responses (SIRs). Event-free survival (EFS) and overall survival (OS) were compared by number and size of pulmonary metastases within two cohorts: (1) RCR treated with additional DD-4A without lung radiation therapy (RT) and (2) SIR treated with the original three drugs plus cyclophosphamide/etoposide (Regimen M) with lung RT. The multivariable Cox proportional hazards model for EFS and OS stratified by treatment assessed the impact of the number and size of pulmonary metastases adjusted for tumor 1q gain. RESULTS AREN0533 enrolled 288 children with stage IV pulmonary-only metastases, of whom 251 met inclusion criteria for outcome analyses. In the RCR cohort (n = 105), EFS and OS were not significantly different based on the number of lung metastases, whereas size of pulmonary metastases was significantly associated with EFS ( P = .022), but not OS. In the SIR cohort (n = 146), EFS and OS did not differ by the number or size of lung metastases. In multivariable models, neither number nor size of lung metastases was significantly associated with EFS or OS although 1q gain was significant (EFS P = .0015; OS P = .039) after adjustment for these factors. CONCLUSION 1q gain is a superior prognostic indicator to pulmonary tumor burden in patients with FHWT with pulmonary-only metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wilms TumorLung NeoplasmsKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleChild, PreschoolTumor BurdenChildInfantVincristineDoxorubicinDactinomycinCyclophosphamide

Substanzen

VincristineDoxorubicinDactinomycinCyclophosphamide

Autor:innen und Institutionen

  • British Columbia Children's Hospital, Vancouver, BC, Canada.
  • Children's Healthcare of Atlanta, Atlanta, GA.
  • University of Southern California and Children's Oncology Group, Los Angeles, CA.
  • Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • UT Southwestern/Simmons Cancer Center, Dallas, TX.
  • Medical University of South Carolina, Charleston, SC.

ORCID-Profile: David B Dix, Lindsay A Renfro, Maddy Artunduaga, Jesse K Sandberg, Jennifer H Aldrink, Daniel J Benedetti, Conrad V Fernandez, Jeffrey S Dome, Elizabeth A Mullen, James I Geller

Förderung

  • NCI NIH HHS

Zitieren

APA

Dix, D. B., Khanna, G., Renfro, L. A., Tfirn, I. C., Smith, E. A., Artunduaga, M., Eklund, M. J., Sandberg, J. K., Parsons, L. N., Kalapurakal, J. A., Ehrlich, P. F., Aldrink, J. H., Glick, R. D., Benedetti, D. J., Fernandez, C. V., Dome, J. S., Mullen, E. A., Geller, J. I., & COG Renal Tumor Committee (2025). Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00532

Vancouver

Dix DB, Khanna G, Renfro LA, Tfirn IC, Smith EA, Artunduaga M, et al. Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00532

BibTeX
@article{Dix2025,
  author = {Dix, David B and Khanna, Geetika and Renfro, Lindsay A and Tfirn, Ian C and Smith, Ethan A and Artunduaga, Maddy and Eklund, Meryle J and Sandberg, Jesse K and Parsons, Lauren N and Kalapurakal, John A and Ehrlich, Peter F and Aldrink, Jennifer H and Glick, Richard D and Benedetti, Daniel J and Fernandez, Conrad V and Dome, Jeffrey S and Mullen, Elizabeth A and Geller, James I and COG Renal Tumor Committee, COG Renal Tumor Committee},
  title = {Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-25-00532}
}
Kostenlos starten →